A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo

Stacy M. Chimento, Meggan Newland, Carlos Ricotti, Steven Nistico, Paolo Romanelli

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
JournalJournal of Drugs in Dermatology
Volume7
Issue number3
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo'. Together they form a unique fingerprint.

  • Cite this